Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Nuevolution in connection with a directed share issue
Mandate

Vinge advises Nuevolution in connection with a directed share issue

May 25, 2018

The board of directors of Nuevolution has resolved on a directed new issue of shares, whereby Nuevolution will raise proceeds of approximately SEK 110 million, before issue costs.

The share issue is directed to a number of selected Swedish and international investors, on the basis of an accelerated bookbuilding process conducted by Carnegie Investment Bank AB (publ) and Redeye AB.

Nuevolution AB (publ) is a small molecule drug discovery biotech company. The company’s shares are admitted to trading on Nasdaq First North Premier.

Vinge’s team has consisted of Dain Hård Nevonen, David Andersson, Malte Hedlund and Stephanie Stiernstedt.

Related

Naval Group signs contract for four defence and intervention frigates (FDI) for the Royal Swedish Navy

 Vinge has advised Naval Group in connection with the negotiations with the Swedish Defence Materiel Administration (FMV) for the procurement of four defence and intervention frigates (FDI) for the Swedish Navy. The contract was signed on 31 August 2026 in Stockholm. Naval Group has been selected as a strategic partner by the Swedish Government to rapidly strengthen and modernise its fleet's capabilities.
September 08, 2026

Vinge advises Axcel and Sanviva on the acquisitions of DermaCura and YourRad

 Vinge has advised Axcel Elevate I and Sanviva in connection with the acquisitions of DermaCura and YourRad.
September 07, 2026

Vinge advises Revivo Group on the acquisition of Premator

 Revivo Group AB has acquired all the shares in Premator AB, the parent company of a group operating in the field of advanced surface treatment with extensive experience in shot blasting, anti-corrosion painting and related services. Operations are conducted in Sweden, Norway and Denmark.
September 03, 2026